Compare Supplements

Side-by-side comparison of 1 supplements

Ela3.0

Elamipretide

Limited safety

Evidence

Evidence Score3/10

Studies: 12

Meta-analyses: 1

Dosage & timing

Dosage:

Trial regimen was 40 mg/day subcutaneously (PMM, Barth, AMD); cardiology trials used intravenous infusion. There is NO validated consumer dose — it is an investigational drug.

Best Time:

Any time

Can take on empty stomach

Form:

Subcutaneous injection (investigational, trial-only)

What you'll notice

➖ No benefit on pivotal myopathy endpointsneutral

24 weeks

➖ No reduction in heart-attack infarct sizeneutral

Acute

🫀 Open-label signal in Barth syndromepositive

Months to years

Safety

Limited safety

Contraindications:

Pregnancy and breastfeeding (not studied)
Use outside a clinical trial or physician oversight (investigational, unapproved drug)
Known hypersensitivity to the peptide or excipients

Drug Interactions:

Other investigational / cardiac-active drugs

Side Effects:

Injection-site reactionsLocal pain / erythema at injection siteUnknown effects from grey-market product

Want to compare more supplements?

Loading comparison...